6 Top Gainers In Pharma Sector (MRTX, NK, GNCA...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Navidea Biopharmaceuticals Inc (NAVB)

Gained 37.60% to close Monday's (June 3) trading at $1.72.

News: No news

Recent event:

On May 8, the Company reported first quarter 2019 financial results.

The net loss attributable to common stockholders for the first quarter of 2019 narrowed to $2.4 million or $0.24 per share from $6.7 million or $0.83 per share for the same period in 2018.

Total revenues for the first quarter of 2019 declined to $136,000 from $276,000 in the same period of 2018, primarily due to a reduction in grant revenue from the NIH supporting Manocept development.

2. Mirati Therapeutics Inc. (MRTX)

Gained 31.58% to close Monday's trading at $89.20.

News: Mirati stock rose following presentation of Amgen's encouraging phase I data of KRAS G12C inhibitor AMG 510 at the ASCO meeting.

Miratis is also developing a KRAS G12C inhibitor by the name MRTX849, and a phase 1/2 multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors With KRAS G12C mutation was started in January of this year.

3. ARCA biopharma Inc. (ABIO)

ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.

The Company's lead product candidate is Gencaro, which is in development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).

Gained 27.12% to close Monday's trading at $7.36.

News: No news

Near-term Catalyst:

Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.

4. NantKwest Inc. (NK)

Gained 25.24% to close Monday's trading at $1.29.

News: The Company's t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma.

5. ASLAN Pharmaceuticals Limited (ASLN)

ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company.

Gained 16.83% to close Monday's trading at $3.40.

News: No news

Clinical Trials & Near-term Catalysts:

-- A pivotal study of Varlitinib in second-line biliary tract cancer, dubbed TreeTopp, is underway. The topline data from this study is expected in the second half of 2019. -- A single-arm study of Varlitinib in second-line biliary tract cancer in China is ongoing and data readout is expected after the TreeTopp study. -- A phase II study of ASLAN003 in acute myeloid leukemia is underway. -- A phase I study of ASLAN004 in atopic dermatitis is ongoing.

6. Genocea Biosciences Inc. (GNCA)

Gained 19.61% to close Monday's trading at $6.71.

News: The Company announced clinical results from its ongoing Phase 1/2a trial for GEN-009, its lead neoantigen vaccine candidate.

According to the Company, in the five patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered.